Unlocking the full potential
of highly potent anticancer drugs

We aim to deliver the best anticancer treatments to patients by a simple subcutaneous injection.

Despite all the efforts in the fight against cancer, some tumors are still resistant to currently available treatments. Highly active pharmaceutical ingredients (HPAPI) are drugs 100 to 1000 times more active than traditional chemotherapies. Unfortunately, patients cannot benefit from HPAPIs as they are currently impossible to administer in their current form. Imescia’s unique technology allows a simple subcutaneous injection of HPAPI in the form of a novel polymer prodrug.

TECHNOLOGY

Imescia’s technology is the first capable of innocuous subcutaneous administration of irritant / vesicant anticancer HPAPI.

HPAPIs have not reached the patient due to three limitations:

  1. Their poor solubility makes them impossible to administer intravenously
  2. A pill cannot be made from them due to their poor oral bioavailability
  3. Their high activity comes at a cost of high toxicities that must be managed

Thanks to our extremely hydrophilic polymer, we can solubilize even the most insoluble small molecules. Our subcutaneous approach allows rapid and high bioavailability. The enhanced pharmacokinetics profile at an optimal dosing, below the toxicity level and above the therapeutic level, greatly decreases the toxicities of the HPAPI and unlocks their true therapeutic potential.

Imescia's technology addresses HPAPI limitations

Simple subcutaneous injection

Pharmacokinetics of different administration routes

Imescia’s subcutaneous long release enhances the efficacy of HPAPI

We are advancing in the preclinical development of our lead product IMA-01, based on a highly potent anticancer drug.

With IMA-01 we seek to address tumors with an important unmet medical need. Our simple-to-use subcutaneous administration approach will allow a better treatment efficacy with fewer toxicities and a simplified treatment for the patient as opposed to an intravenous infusion.

We are actively looking for partnership opportunities to adapt our technology to the best HPAPIs

Our prodrug polymer technology is a platform that can be adapted to a wide variety of small molecules, peptides and oligonucleotides.

Small molecules

Peptides

Oligonucleotides

We improve API solubility, stability, pharmacokinetics (enhanced half-life) and do not need to use additional surfactants or lipids for the formulation. This is particularly of interest for small molecules HPAPI, peptides and oligonucleotides. Get in touch with us to learn more about the technology.

ABOUT IMESCIA

Founded in 2019, Imescia is a spin-off company from the Institut Galien Paris-Sud, co-founded by Tanguy Boissenot CEO (Pharm.D., Ph.D.), Alexandre Bordat CTO (Ecole polytechnique, Ph.D.), Nicolas Tsapis (Ph.D., CNRS researcher), and Julien Nicolas (Ph.D., CNRS researcher). The company is the result of four years of fundamental research at the Institut Galien Paris-Sud. The team has the expertise in polymer synthesis and drug delivery systems.

OUR TEAM

Tanguy BOISSENOT
CEO co-founder
Pharm.D. Ph.D

Alexandre BORDAT
CTO co-founder
Ecole polytechnique - Ph.D

Nada IBRAHIM
Head of Chemistry
Ph.D.

Nicolas TSAPIS
Scientific advisor co-founder
Ph.D - DR CNRS
Physical-chemistry

Julien NICOLAS
Scientific advisor co-founder
Ph.D - DR CNRS
Polymer chemistry

CONTACT US

12 + 8 =

contact@imescia.com

5, rue Jean-Baptiste Clément
92290 Châtenay-Malabry

PARTNERS

MENTORING

GRANTS

ACADEMIC FUNDING

THANKS TO IPSEN FOR LABORATORY EQUIPMENT